THE  INFLUENCE OF SPIRONOLACTONE  ON THE  COURSE  OF  EXPERIMENTAL CHRONIC RENAL FAILURE AND  MYOCARDIUM  HYPERTROPHY IN WISTAR  RATS

A. Zh. Karabaeva; M. M. Parastaeva; O. N. Beresneva; A. V. Smirnov; A. M. Essaian; I. G. Kayukov

doi:10.24884/1561-6274-2008-12-1-64-68

THE INFLUENCE OF SPIRONOLACTONE ON THE COURSE OF EXPERIMENTAL CHRONIC RENAL FAILURE AND MYOCARDIUM HYPERTROPHY IN WISTAR RATS

A. Zh. Karabaeva, M. M. Parastaeva, O. N. Beresneva, A. V. Smirnov, A. M. Essaian, I. G. Kayukov

https://doi.org/10.24884/1561-6274-2008-12-1-64-68

Full Text:

PDF (Rus) |

Generate QR code

Abstract

THE AIM of the investigation was to estimate the influence of spironolactone therapy on progression of experimental chroic renal failure (CRF) and myocardium hypertrophy in rats. MATERIAL AND METHODS. The investigation was performed in Wistar rats with experimental CRF (model of 5/6 nephrectomy). The first group of animals was given spironolactone (0.2 mg/day) after nephrectomy. The animal of the second group did not receive spironolactone. The third group (control) consisted of sham-operated rats. Mean arterial pressure and heart rate were measured, daily urine was collected. In the blood serum taken during killing the content of aldosterone, urea, creatinine, electrolytes and total protein were determined. RESULTS. The myocardium hypertrophy index in the first group did not reliably differ from the third group (2.52±0.06 and 2.35± 0.09 respectively, p>0.05), while in the second group (2.8±0.11) a reliable difference was obtained relative to control (p<0.05). CONCLUSION. Blockade of aldosterone receptors with spironolactone provides a cardioprotective effect in Wistar rats with 5/6 nephrectomy.

Keywords

aldosterone, spironolactone, arterial hypertension, left ventricle hypertrophy, experimental chronic renal failure

About the Authors

A. Zh. Karabaeva

Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-Петербург
Russian Federation

M. M. Parastaeva

O. N. Beresneva

A. V. Smirnov

A. M. Essaian

I. G. Kayukov

References

1. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патологические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-153

2. Шишкин АН. Современные проблемы уремической кардиопатии. Нефрология 2003; 7(1): 14-20

3. McMahon AC, Greenwald SE, Dodd SM et al. Prolonged calcium transient and myocardial remodeling in early experimental uremia. Nephr Dial Transplant 2002; 17(5): 759-7642

4. Кутырина ИМ, Руденко ТЕ, Швецов МЮ, Кушнир ВВ. Факторы риска сердечно-сосудистых осложнений у больных на додиализной стадии хронической почечной недостаточности. Тер арх 2006; 5: 45-50

5. Сторожаков ГИ, Гендлин ГЕ, Томилина НА и др. Поражение сердечно-сосудистой системы при хронической почечной недостаточности. Рос Мед Журнал 2005; 2: 4-8

6. Смирнов АВ, Добронравов ВА, Румянцев АШ и др. Факторы риска ИБС у больных, получающих лечение гемодиализом. Нефрология 2003; 7(приложение 1): 7-13

7. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Advanc renal replacement ther 1997; 4(3): 2212-2246

8. Ishikawa M, Akishita M, Kozaki K et al. Amino-terminal fragment (1-34) of PTH inhibits migration and proliferation of cultured vascular smooth muscle cells. Atherosclerosis 1998; 136(1): 59-66

9. Qing DP, Ding H, Vadgama J et al. Elevated myocardial cytosolic calcium impairs insulin-like growth factor-1-stimulated protein synthesis in chronic renal failure. J Am Soc Nephrol 1999; 19(1): 84-92

10. Dhein S, Rohnert P, Markau S. Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats. J Am Col Cardiol 2000; 36(2): 608-617

11. Hatori N, Havu N, Hofman-Bang C et al. Myocardial morphology and cardiac function in rats with renal failure. Jap Circ J 2000; 64(8): 606-610

12. Cortassa S, Aon MA, Marban E. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J 2003; 84(4): 2734-2755

13. Norris K, Vaughn C. The role of renin-angiotensin-aldosterone system in chronic kidney disease. Expert Rev Cardiovasc Ther 2003; 1(1): 51-63

14. Epstain M. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 2001; 40(7): 573-583

15. Duprez D, de Buyzere M, Rietzchel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2; 327-334

16. Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522

17. Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in glomerular microcirculation. J Am Soc Nephrol 2003; 14(9): 2253-2255

18. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1246

19. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 2001; 94(8): 378-383

20. Nishiyama A, Abe Y. Aldosterone and renal injury. Folia Pharmacol Jap 2004; 124(2): 101-109

21. Oberleithner H, Ludwig T, Iethmuller C et al. Human endothelium: target for aldosterone. Hypertension 2004; 43(5): 952-957

22. Jucknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol 2004; 286(6): F1059-F1062

23. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbility and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717

24. Gross F, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anutic hemodyalysis patients. Am J Kidney Dis 2005; 46(1): 94-101

25. Harris C, Meyer T, Brenner BM. Nephron ablation to renal injury. The Kidney. Eds. Brenner BM, Rector FC. Philadelphia, London, Tokyo 1986; 1555-1565

26. Okoshi K, Ribero HB, Okoshi MP et al. Improved systolic ventricular function with normal myocardial mechanics in compensated cardiac hypertrophy. Jpn Heart J 2004; 45(4): 647-656

27. Sevilla M, Voces F, Carron R et al. Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawl. Life Sci 2004; 75(2): 881-891

28. Rocha R, Martin-Berger CL, Yang P et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836

29. Barr CS, Lang CC, Hanson J et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery diseases. Am J Cardiol 1995; 76: 1259–1265

30. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003; 16(2): 85-94

31. Rocha R, Stier CTJ, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878

32. Struthers AD. Aldosterone an important mediator of cardiac remodeling in heart failure. Br J Cardiol 2005; 12(3): 211-218

33. Connell JCM, Davies E. The new biology of aldosterone. J Endocrinol 2005; 186: 1-20.

34. Cases A, Bragulat E, Serradell M et al. Endothelial dysfunction in chronic renal failure. Nephrologia 2003; 23(4): 42-51.

35. Weber KT. Targeting pathological remodeling. Concepts of cardioprotection and reparation. Circulation 2000; 102: 1342-1345

Review

For citations:

Karabaeva A.Zh., Parastaeva M.M., Beresneva O.N., Smirnov A.V., Essaian A.M., Kayukov I.G. THE INFLUENCE OF SPIRONOLACTONE ON THE COURSE OF EXPERIMENTAL CHRONIC RENAL FAILURE AND MYOCARDIUM HYPERTROPHY IN WISTAR RATS. Nephrology (Saint-Petersburg). 2008;12(1):64-68. (In Russ.) https://doi.org/10.24884/1561-6274-2008-12-1-64-68

ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Nephrology (Saint-Petersburg)